WallStSmart

Canopy Growth Corp (CGC)vsTeva Pharma Industries Ltd ADR (TEVA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Teva Pharma Industries Ltd ADR generates 6132% more annual revenue ($17.35B vs $278.39M). TEVA leads profitability with a 9.0% profit margin vs -117.3%. TEVA earns a higher WallStSmart Score of 66/100 (B-).

CGC

Avoid

30

out of 100

Grade: F

Growth: 2.7Profit: 2.0Value: 5.0Quality: 6.5
Piotroski: 5/9Altman Z: -17.32

TEVA

Strong Buy

66

out of 100

Grade: B-

Growth: 6.0Profit: 7.0Value: 6.3Quality: 4.0
Piotroski: 6/9Altman Z: 0.28

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CGC1 strengths · Avg: 10.0/10
Price/BookValuation
0.7x10/10

Reasonable price relative to book value

TEVA2 strengths · Avg: 9.0/10
EPS GrowthGrowth
72.2%10/10

Earnings expanding 72.2% YoY

PEG RatioValuation
0.858/10

Growing faster than its price suggests

Areas to Watch

CGC4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$467.04M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-33.6%2/10

ROE of -33.6% — below average capital efficiency

Revenue GrowthGrowth
-0.3%2/10

Revenue declined 0.3%

TEVA4 concerns · Avg: 3.0/10
P/E RatioValuation
25.8x4/10

Moderate valuation

Revenue GrowthGrowth
2.3%4/10

2.3% revenue growth

Free Cash FlowQuality
$-208.00M2/10

Negative free cash flow — burning cash

Altman Z-ScoreHealth
0.282/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : CGC

The strongest argument for CGC centers on Price/Book.

Bull Case : TEVA

The strongest argument for TEVA centers on EPS Growth, PEG Ratio. PEG of 0.85 suggests the stock is reasonably priced for its growth.

Bear Case : CGC

The primary concerns for CGC are EPS Growth, Market Cap, Return on Equity.

Bear Case : TEVA

The primary concerns for TEVA are P/E Ratio, Revenue Growth, Free Cash Flow. Debt-to-equity of 2.05 is elevated, increasing financial risk.

Key Dynamics to Monitor

CGC profiles as a turnaround stock while TEVA is a value play — different risk/reward profiles.

CGC carries more volatility with a beta of 2.41 — expect wider price swings.

TEVA is growing revenue faster at 2.3% — sustainability is the question.

CGC generates stronger free cash flow (-26M), providing more financial flexibility.

Bottom Line

TEVA scores higher overall (66/100 vs 30/100). Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Canopy Growth Corp

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Canopy Growth Corporation is engaged in the production, distribution and sale of cannabis and hemp-based products for recreational and medical purposes primarily in Canada, the United States, and Germany. The company is headquartered in Smiths Falls, Canada.

Teva Pharma Industries Ltd ADR

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic drugs, specialty drugs, and biopharmaceuticals in North America, Europe, and internationally. The company is headquartered in Petach Tikva, Israel.

Want to dig deeper into these stocks?